Poster
16

High Throughput Screening cascade to generate highly selective hits for PIM3 kinase

Authors

P Dupuis1; M Ramnath1; A Otto-Bruc1; L Breuils1; S Davies1; P Ratcliffe3; F Moreau1C Legros2
1 Eurofins Cerep SA, France;  2 Eurofins Discovery, United States;  3 Eurofins Integrated Discovery UK Ltd, France

Abstract

The proto-oncogene Proviral Integration site for Moloney murine leukemia virus 3 Kinase (PIM3K) is a proto-oncogene serine/threonine-protein kinase involved in numerous cancers. Identification of new PIM kinase inhibitor scaffolds is therefore highly valuable for the development of new anticancer therapies.

Kinase discovery efforts are usually particularly challenging, because of conserved active sites and high structural homology between kinases leading to safety liabilities. Here we present a comprehensive and robust screening cascade to rapidly identify selective PIM3 kinase inhibitors from our proprietary libraries. Moreover, subsequent to primary screening, novel PIM3K inhibitors can be profiled in analogous selectivity assays and confirmed in both orthogonal and cellular target engagement (TE) assays.



High quality, recombinant, active PIM3K was produced in-house to develop a robust high throughput ADP-Glo™ primary assay used to screen Eurofins Discoveris Diversity Focused and Hinge binder libraries (73,000 compounds). High-quality data sets were obtained (Z’ ≤ 0.86 ± 0.05, n≤211; SNR ≤ 35.1 ± 2.7) with a hit rate of 1.54% enabling the selection of 1,000 hits (946 confirmed in ADP-Glo dose response curves, exhibiting pIC50 from 3.4 to >7.5). Those hits are in the process of being confirmed in both a PIM3 cellular NanoBRET™ (TE) assay (Z’ > 0.6, SNR 5-6), and a mass spectrometry assay monitoring of site-specific phosphorylation events. Further triaging will take place employing Eurofins Discovery's proprietary KinaseProfiler™ and KINOMEscan® platforms to investigate their selectivity against PIM1 & PIM2 kinases (IC50 & KD) as well as the whole kinome.



Overall, a robust screening cascade has successfully been established in order to deliver highly selective and tractable kinases inhibitors in just a few short weeks.

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Login
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021